These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 25011029)

  • 1. To the editor.
    Sizmaz S; Esen E; Barman S; Demircan N
    Retina; 2014 Aug; 34(8):e19-20. PubMed ID: 25011029
    [No Abstract]   [Full Text] [Related]  

  • 2. Systemic Mineralocorticoid Antagonists in the Treatment of Central Serous Chorioretinopathy.
    Yang D; Eliott D
    Semin Ophthalmol; 2017; 32(1):36-42. PubMed ID: 27929707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reply: To PMID 23719402.
    Behar-Cohen F; Bousquet E
    Retina; 2014 Aug; 34(8):e20-1. PubMed ID: 25054345
    [No Abstract]   [Full Text] [Related]  

  • 4. The use of eplerenone in therapy-resistant chronic central serous chorioretinopathy.
    Breukink MB; den Hollander AI; Keunen JE; Boon CJ; Hoyng CB
    Acta Ophthalmol; 2014 Sep; 92(6):e488-90. PubMed ID: 24698599
    [No Abstract]   [Full Text] [Related]  

  • 5. A new treatment approach - Eplerenone - in central serous chorioretinopathy - Case report.
    Cioboata M; Alexandrescu C; Hopinca CA; Pienaru MC; Merticariu A; Schmitzer S
    J Med Life; 2016; 9(1):92-94. PubMed ID: 27713772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CENTRAL SEROUS CHORIORETINOPATHY TREATED WITH MINERALOCORTICOID ANTAGONISTS: A ONE-YEAR PILOT STUDY.
    Ghadiali Q; Jung JJ; Yu S; Patel SN; Yannuzzi LA
    Retina; 2016 Mar; 36(3):611-8. PubMed ID: 26405766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of diffuse retinal pigment epitheliopathies by antialdosterones or by photodynamic therapy].
    Kouassi AC; Masse H; Lebreton O; Weber M
    J Fr Ophtalmol; 2015 Jun; 38(6):e129. PubMed ID: 25976130
    [No Abstract]   [Full Text] [Related]  

  • 8. Mineralocorticoid antagonists in the treatment of central serous chorioetinopathy: Review of the pre-clinical and clinical evidence.
    Bousquet E; Zhao M; Daruich A; Behar-Cohen F
    Exp Eye Res; 2019 Oct; 187():107754. PubMed ID: 31401003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study.
    Bousquet E; Beydoun T; Zhao M; Hassan L; Offret O; Behar-Cohen F
    Retina; 2013; 33(10):2096-102. PubMed ID: 23719402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mineralocorticoid receptor inhibitor for long-standing central serous chorioretinopathy.
    Suzuki A; Takano Y; Ando Y; Ogawa J; Ishida M; Baba A; Imamura Y
    Acta Ophthalmol; 2018 Aug; 96(5):e662-e663. PubMed ID: 29671951
    [No Abstract]   [Full Text] [Related]  

  • 11. The use of mineralocorticoid receptor antagonists in chronic central serous chorioretinopathy.
    Pociej-Marciak W; Karska-Basta I; Ozog-Baran J; Kubicka-Trzaska A; Filemonowicz-Skoczek A; Romanowska-Dixon B
    Klin Oczna; 2016 Aug; 118(1):48-54. PubMed ID: 29715409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infographic: Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months: the VICI study.
    Yusuf IH; Henein C; Sivaprasad S
    Eye (Lond); 2024 Aug; 38(Suppl 2):33-34. PubMed ID: 37085716
    [No Abstract]   [Full Text] [Related]  

  • 13. SPIRONOLACTONE FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY: A RANDOMIZED CONTROLLED CROSSOVER STUDY.
    Bousquet E; Beydoun T; Rothschild PR; Bergin C; Zhao M; Batista R; Brandely ML; Couraud B; Farman N; Gaudric A; Chast F; Behar-Cohen F
    Retina; 2015 Dec; 35(12):2505-15. PubMed ID: 26017871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central serous chorioretinopathy treatment with spironolactone: a challenge-rechallenge case.
    Ryan EH; Pulido CM
    Retin Cases Brief Rep; 2015; 9(3):235-8. PubMed ID: 25790318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eplerenone for chronic central serous chorioretinopathy.
    Stanescu-Segall D; Touhami S; Bodaghi B; LeHoang P
    Lancet; 2020 Nov; 396(10262):1556-1557. PubMed ID: 33189169
    [No Abstract]   [Full Text] [Related]  

  • 16. Eplerenone for chronic central serous chorioretinopathy.
    Sacconi R; Borrelli E; Querques G
    Lancet; 2020 Nov; 396(10262):1556. PubMed ID: 33189168
    [No Abstract]   [Full Text] [Related]  

  • 17. A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROL PILOT STUDY OF EPLERENONE FOR THE TREATMENT OF CENTRAL SEROUS CHORIORETINOPATHY (ECSELSIOR).
    Rahimy E; Pitcher JD; Hsu J; Adam MK; Shahlaee A; Samara WA; Vander JF; Kaiser RS; Chiang A; Spirn MJ; Fineman MS
    Retina; 2018 May; 38(5):962-969. PubMed ID: 28426624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mineralocorticoid receptor antagonists in chronic central serous chorioretinopathy.
    Sanhueza A; González R
    Medwave; 2020 Sep; 20(8):e8036. PubMed ID: 33017387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eplerenone in patients with chronic recurring central serous chorioretinopathy.
    Leisser C; Hirnschall N; Hackl C; Plasenzotti P; Findl O
    Eur J Ophthalmol; 2016 Aug; 26(5):479-84. PubMed ID: 26692062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central serous chorioretinopathy after nasal corticosteroids in the aviator.
    Ben Salem S; Sithom A; Ben Dhia I; Khelifi T; Askri H; Ayed A
    Tunis Med; 2016 Dec; 94(12):893. PubMed ID: 28994894
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.